 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C10H11F2NO2 |
| Molar mass | 215.200 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Difluoromethylenedioxyamphetamine (DFMDA,DiFMDA) is a substituted derivative of3,4-methylenedioxyamphetamine (MDA), which was developed byDaniel Trachsel and coworkers, along with the corresponding fluorinated derivatives of MDMA, MDEA, BDB and MBDB, with the aim of finding a non-neurotoxic drug able to be used as a less harmful substitute forentactogenic drugs such asMDMA. Since a major route of the normal metabolism of these compounds is scission of themethylenedioxy ring, producing neurotoxic metabolites such asalpha-methyldopamine, it was hoped that the difluoromethylenedioxybioisostere would show increased metabolic stability and less toxicity.[1][2][3]
These compounds have not yet been tested in animals to verify whether they show similar pharmacological activity to the non-fluorinated parent compounds, althoughin vitro binding studies show DFMDA to have aSERT affinity in between that of MDA and MDMA.[4] It is also now generally accepted that MDMAneurotoxicity results from a variety of different causes and is not solely due to accumulation of alpha-methyldopamine,[5][6][7] making it unclear how much less neurotoxic DFMDA and related drugs would be in practice.
